Abstract
Total lymphoid irradiation (TLI)—a technique developed at Stanford University Medical Center, California, originally for treatment of stage III Hodgkin's disease—is yielding such "encouraging" results in patients with intractable rheumatoid arthritis that its application to a broader range of autoimmune diseases and organ transplantation is now being investigated. In a keynote address at the recent meeting of the American Society of Therapeutic Radiologists (ASTR) in Orlando, Fla, Henry S. Kaplan, MD, director of the Cancer Biology Research Laboratory at Stanford, said that although use of TLI for autoimmune disease is still very much investigational, it would appear, "based on our limited experience so far, that this will become a new treatment for patients with very far advanced and crippling autoimmune disease." Still, he emphasized the experimental nature of this work, telling the audience: "We would be quite alarmed if there were any widespread move to adopt this as a treatment for
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: JAMA: The Journal of the American Medical Association
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
